301 results on '"Maurel J"'
Search Results
2. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
3. MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial
4. Targeted transcriptomic analysis of pancreatic adenocarcinoma in EUS-FNA samples by NanoString technology
5. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial
6. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study
7. Lithium as a disease-modifying agent for prion diseases
8. A new clinically applicable immune-metabolic signature (IMMETCOLS) reveals metabolic singularities in consensus molecular subtypes (CMS) in colorectal cancer
9. 763P Combined gene signature (T-cell inflamed gene expression profile – TcellinfGEP – & IMMETCOLS) identifies a metabolic rewiring program, key for immune evasion
10. 383P An exosome-based liquid biopsy assay for predicting therapeutic outcomes in patients with metastatic colorectal cancer treated with anti-EGFR therapy: Results from prospective, first-line, PULSE and POSIBA trials
11. 433P Pre-treatment and post-treatment MRI extramural venous invasion, predicts disease-free survival and overall survival, in locally advanced rectal cancer
12. 352P Mutations of SMAD4 and FBXW7 predict poor outcome in TP53-driven metastatic colorectal cancer
13. 338P A new clinically applicable immune-metabolic signature (IMMETCOLS) reveals metabolic singularities in consensus molecular subtypes (CMS) in colorectal cancer
14. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer
15. Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer
16. Impact of Microscopic Incomplete Resection for Colorectal Liver Metastases on Surgical Margin Recurrence: R1-Contact vs. R1≪1mm Margin Width
17. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study
18. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer
19. 416P Randomized phase II trial of second-line FOLFIRI-panitumumab vs FOLFIRI alone in Ras wild type (wt) metastatic colorectal cancer (mCRC) patients beyond progression to first-line FOLFOX-panitumumab: BEYOND study (GEMCAD 17-01)
20. 442P A phase I-II multicenter trial with avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients. GEMCAD 16-02 (AVEVAC trial)
21. 996P An immune-metabolic signature correlates with immune-suppressive patterns and with outcome, across tumor types
22. 81P Baseline circulating CD4+PD1+high T cells (TCD4PD1H) as predictors of survival in patients (P) with solid tumors treated with immune-checkpoint inhibitors (ICI)
23. P-228 Phase II multicentric randomized controlled trial to compare first-line treatment with FOLFOX6m + mAB alone or in combination with liver chemoembolization (Lifepearls-Irinotecan) in poor prognosis colorectal cancer with liver-limited disease
24. Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD1402 Trial
25. Phase II trial of neoadjuvant mFOLFOX 6 with panitumumab (P) in T3 rectal cancer with clear mesorectal fascia (MRF) and KRAS, NRAS, BRAF, PI3KCA wild type (4WT). GEMCAD 1601 PIER trial
26. PL03.13 Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2)
27. 512MO FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
28. LBA68 FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
29. 605P First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort
30. 595P The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)
31. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy
32. 29P Characterization of T cell responses induced by the individualized mRNA neoantigen vaccine autogene cevumeran in adjuvant stage II (high risk)/stage III colorectal cancer (CRC) patients (pts) from the biomarker cohort of the phase II BNT122-01 trial.
33. 548P Molecular pre-screening using comprehensive gene panels offered by clinical trials (CT)
34. 474P Prognostic and predictive role of Consensus Molecular Subtypes (CMS) determined by immunohistochemistry in metastatic colorectal cancer (mCRC)
35. 471P Identification and validation of a new prognostic score in metastatic colorectal cancer (mCRC): GEMCAD score
36. 109P Subpopulations of peripheral blood lymphocytes and response to immunotherapy across cancer-types
37. 476P Mutational profiling allows the stratification of metastatic colorectal cancer patients with poor prognosis
38. 427P Value of magnetic resonance diffusion weighted imaging in the identification of complete responder patients with rectal cancer treated with neoadjuvant therapy
39. Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO
40. Randomized phase II clinical trial to evaluate the efficacy of second line FOLFIRI-panitumumab in patients with RAS wild -type metastatic colorectal cancer who have received FOLFOXpanitumumab in first -line (BEYOND)
41. Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02)
42. DTIC + carboplatin + IFNα2a in metastatic melanoma: Renal Cancer and Melanoma Spanish Group.
43. Evidence of improving survival of patients with rectal cancer in France: a population based study
44. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study
45. Mutational profile of non-metastatic anal squamous cell carcinoma: a restrictive high impact genetic variants analysis
46. Immune signatures identify three immune clusters in mCRC, with potential clinical implications
47. Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study
48. Whole-exome sequencing of non-metastatic anal squamous cell carcinoma: a prognostic genetic variants analysis
49. Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND)
50. Do we need adjuvant therapy in patients with rectal cancer and pathologic complete response, after conventional preoperative chemoradiation and laparoscopic (LapTME) or Transanal total mesorectal excision (TaTME)?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.